Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$5.49 Average Target Price from Analysts

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have received an average rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and four have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is C$5.49.

Several analysts have issued reports on MDP shares. Ventum Financial upped their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a report on Thursday, January 30th. Stifel Canada cut shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the stock from C$6.00 to C$3.45 in a research report on Friday, February 7th. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP opened at C$2.12 on Friday. The firm has a market capitalization of C$47.46 million, a P/E ratio of 10.14 and a beta of 1.96. The firm’s 50-day moving average price is C$2.67 and its 200-day moving average price is C$2.89. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.